Accurate Assessment of Vascularity of Focal Hepatic Lesions in Arterial Phase Imaging

Feiqian Wang,Kazushi Numata,Litao Ruan
DOI: https://doi.org/10.1148/radiol.2020202780
IF: 19.7
2020-01-01
Radiology
Abstract:HomeRadiologyVol. 297, No. 3 PreviousNext CommunicationsFree AccessLetters to the EditorAccurate Assessment of Vascularity of Focal Hepatic Lesions in Arterial Phase ImagingFeiqian Wang*,†, Kazushi Numata* , Litao Ruan†Feiqian Wang*,†, Kazushi Numata* , Litao Ruan†Author AffiliationsGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, Japan*Department of Ultrasound, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, P.R. China†e-mail: [email protected]Feiqian Wang*,†Kazushi Numata* Litao Ruan†Published Online:Sep 29 2020https://doi.org/10.1148/radiol.2020202780MoreSectionsPDF ToolsImage ViewerAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked In Editor:This letter is to respectfully comment on the study by Dr Joo and colleagues (1) published in the August 2020 issue of Radiology.We noticed that in the Methods section of this article, the authors determined the arterial phase hyperenhancement (APHE) appearance by using gadoxetic acid–enhanced MRI and four-phase multi–detector row CT data (when available). By using CT during hepatic arteriography as a reference, contrast agent–enhanced US with Sonazoid was reported to be more accurate than the gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic (EOB)–enhanced MRI in detecting intratumoral arterial vascularity (2).We evaluated our experience with Sonazoid contrast-enhanced US and EOB-enhanced MRI for 163 untreated hepatocellular carcinomas (HCCs). Among them, 40 lesions (24.5%) showed lack of agreement of the vascular pattern in the arterial phase between EOB-enhanced MRI and Sonazoid contrast-enhanced US. Of these 40 lesions, 26 were diagnosed with APHE by Sonazoid contrast-enhanced US and 17 with APHE by EOB-enhanced MRI. This inconsistency might be due to either of the following: (a) MRI examinations acquire static images, and lesions with a late arterial wash-in appearance in the arterial phase of EOB-enhanced MRI could be misdiagnosed as isovascularity according to images in the early stage of arterial phase; or (b) Sonazoid contrast-enhanced US can successfully capture transient hyperperfusion of contrast agent by performing real-time observations and allowing for slow playback of the video recording. APHE features can be further confirmed by using reinjection technique of Sonazoid contrast-enhanced US (3). Therefore, some research studies have used two modalities (dynamic multiphase CT or Sonazoid contrast-enhanced US) to make a definitive diagnosis of nonhypervascularity in the arterial phase (4,5).In conclusion, for accurate diagnosis of a “no-APHE” lesion, we suggest that a combination of at least two imaging modalities, with Sonazoid contrast-enhanced US as the first choice, may be useful. Accurate classification of no-APHE lesions is necessary to explore pathologic and radiologic features of these difficult-to-diagnose lesions. Further, if APHE lesions are misdiagnosed as no-APHE lesions and followed up accordingly, patients may face a risk of lack of diagnosis of HCC and lack of treatment, leading to poor prognosis.Disclosures of Conflicts of Interest: F.W. disclosed no relevant relationships. K.N. disclosed no relevant relationships. L.R. disclosed no relevant relationships.References1. Joo I, Kim S, Kang T, et al. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology 2020;296(2):335–345. Link, Google Scholar2. Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 2012;22(6):1205–1213. Crossref, Medline, Google Scholar3. Kudo M. Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma. Liver Cancer 2016;5(1):1–7. Medline, Google Scholar4. Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011;34(1):88–94. Crossref, Medline, Google Scholar5. Inoue T, Hyodo T, Korenaga K, et al. Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. J Gastroenterol 2016;51(2):144–152. Crossref, Medline, Google ScholarReferences1. Joo I, Kim SY, Kang TW, et al. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology 2020;296(2):335–345. Link, Google Scholar2. Huh J, Kim SY, Yeh BM, et al. Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver. Korean J Radiol 2015;16(6):1207–1215. Crossref, Medline, Google Scholar3. Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 2012;22(6):1205–1213. Crossref, Medline, Google Scholar4. Basha MAA, AlAzzazy MZ, Ahmed AF, et al. Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study. Eur Radiol 2018;28(6):2592–2603. Crossref, Medline, Google Scholar5. Aubé C, Oberti F, Lonjon J, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int 2017;37(10):1515–1525. Crossref, Medline, Google ScholarReferences1. Joo I, Kim S, Kang T, et al. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology 2020;296(2):335–345. Link, Google Scholar2. Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 2012;22(6):1205–1213. Crossref, Medline, Google Scholar3. Kudo M. Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma. Liver Cancer 2016;5(1):1–7. Medline, Google Scholar4. Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011;34(1):88–94. Crossref, Medline, Google Scholar5. Inoue T, Hyodo T, Korenaga K, et al. Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. J Gastroenterol 2016;51(2):144–152. Crossref, Medline, Google ScholarResponseIjin Joo*, So Yeon Kim† , Jeong Min Lee*Ijin Joo*, So Yeon Kim† , Jeong Min Lee*Author AffiliationsDepartment of Radiology, Seoul National University Hospital, Seoul, Republic of Korea*Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea†e-mail: [email protected]We appreciate the opportunity to respond to the letter regarding our recent study (1) published in the August 2020 issue of Radiology.Because APHE is a prerequisite for the noninvasive diagnosis of HCC, the importance of an accurate assessment of arterial hypervascularity in focal hepatic lesions cannot be overemphasized. We completely agree with the authors’ concern that gadoxetic acid–enhanced MRI can underestimate APHE (2). This is because of the small administered volume and the gadolinium content of the agent as well as the occurrence of transient severe motion. To overcome the drawbacks of gadoxetic acid, we included subtraction images of T1 hyperintense nodules on precontrast images and double-checked APHE on contrast-enhanced CT images obtained within 4 months from MRI available in 71% of patients.As the authors indicated, real-time acquisition of contrast-enhanced US images can allow sensitive detection of APHE, which may be missed on gadoxetic acid–enhanced MRI scans (3). A further study is expected to determine if APHE on contrast-enhanced US images helps to characterize hepatobiliary phase hypointense nodules. However, contrast-enhanced US has limitations with nodules that are invisible on gray-scale US images or in patients with a poor sonic window. A combined approach allowing the interpretation of two different imaging modalities simultaneously can enhance the diagnostic efficacy in characterizing focal hepatic lesions (4). Yet, this combined approach is not recommended by current guidelines for HCC and needs further validation. Furthermore, adding contrast-enhanced US may increase diagnostic costs. Although the utility of contrast-enhanced US with blood pool agents as a secondary examination for diagnosing HCC has been validated (5), the performance of Sonazoid is yet to be corroborated.To circumvent the limitations of gadoxetic acid–enhanced MRI in detecting APHE, we propose another approach for differentiating progressed HCC from lower-grade nodules among hepatobiliary phase hypointense nodules, which adopts the α-fetoprotein level and the multiparametric MRI information. This information is already accessible without an additional imaging study. We suggest that considering multiparametric information can maximize the benefits of gadoxetic acid–enhanced MRI in distinguishing progressed HCC from lower-grade nodules among hepatobiliary phase hypointense nodules without APHE. Disclosures of Conflicts of Interest: I.J. disclosed no relevant relationships. S.Y.K. disclosed no relevant relationships. J.M.L. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: disclosed money to author for consultancy from Samsung Medison; disclosed grants from Bayer Healthcare, Canon Healthcare, GE Healthcare, CMS, Guerbet, Samsung Medison, and Bracco; disclosed payment for lectures from Bayer, Siemens, Samsung Medison, and Guerbet; disclosed stock/stock options from Clariscan. Other relationships: disclosed no relevant relationships.References1. Joo I, Kim SY, Kang TW, et al. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology 2020;296(2):335–345. Link, Google Scholar2. Huh J, Kim SY, Yeh BM, et al. Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver. Korean J Radiol 2015;16(6):1207–1215. Crossref, Medline, Google Scholar3. Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 2012;22(6):1205–1213. Crossref, Medline, Google Scholar4. Basha MAA, AlAzzazy MZ, Ahmed AF, et al. Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study. Eur Radiol 2018;28(6):2592–2603. Crossref, Medline, Google Scholar5. Aubé C, Oberti F, Lonjon J, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int 2017;37(10):1515–1525. Crossref, Medline, Google ScholarArticle HistoryPublished online: Sept 29 2020Published in print: Dec 2020 FiguresReferencesRelatedDetailsRecommended Articles Contrast-enhanced US Approach to the Diagnosis of Focal Liver MassesRadioGraphics2017Volume: 37Issue: 5pp. 1388-1400Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk PatientsRadiology2018Volume: 289Issue: 3pp. 816-830MRI Assessment of Hepatocellular Carcinoma after Local-Regional Therapy: A Comprehensive ReviewRadiology: Imaging Cancer2020Volume: 2Issue: 1Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after SurgeryRadiology2021Volume: 300Issue: 3pp. 572-582Hepatocellular Carcinoma in Evolution: Correlation with CEUS LI-RADSRadioGraphics2022Volume: 42Issue: 4pp. 1028-1042See More RSNA Education Exhibits Under Pressure! Challenging Scenarios of HCC on CT and MRI Â Digital Posters2020Imaging Diagnosis of Hepatocellular Carcinoma in the Era of Molecular Targeted Therapy and ImmunotherapyDigital Posters2022Contrast-Enhanced Ultrasound In HCC Treatment Response Assessment After Microwave AblationDigital Posters2021 RSNA Case Collection LI-RADS 5RSNA Case Collection2022LI-RADS 5RSNA Case Collection2021Focal nodular hyperplasia of the liverRSNA Case Collection2020 Vol. 297, No. 3 Metrics Altmetric Score PDF download
What problem does this paper attempt to address?